BYSI — BeyondSpring Inc.

Summary of BeyondSpring (BYSI) Q4 2021 Earnings Call

1. Key Financial Results and Metrics:

• Q4 2021 Financials:
  • R&D expenses: $5.8 million, down from $8.4 million YoY.
  • G&A expenses: $5.0 million, significantly reduced from $10.4 million YoY, primarily due to lower share-based compensation.
  • Net loss: $9.5 million, improved from $17.6 million YoY.
• Full Year 2021 Financials:
  • R&D expenses: $36.9 million, down from $41.8 million YoY.
  • G&A expenses: $30.7 million, up from $22.6 million YoY, driven by pre-commercialization costs.
  • Net loss: $64.2 million, slightly higher than $61.0 million in 2020.
• Cash Position: As of December 31, 2021, cash and short-term investments totaled $72.4 million, expected to support operations for the next year.

2. Strategic Updates and Business Highlights:

• Plinabulin Development:
  • Ongoing discussions with China’s NMPA for the NDA of Plinabulin in combination with G-CSF for chemotherapy-induced neutropenia (CIN).
  • Positive top-line data from the Phase 3 DUBLIN-3 study for non-small cell lung cancer (NSCLC) presented at ESMO, showing improved survival rates.
  • Strategic partnership with Hengrui Pharmaceuticals for Plinabulin's development and commercialization in Greater China, including a potential $171 million in milestone payments.
• Pipeline Expansion: Continued development of Plinabulin in immuno-oncology combinations and other cancer types.

3. Forward Guidance and Outlook:

• Targeting NDA filing for Plinabulin in China by year-end 2022.
• Ongoing discussions with the FDA regarding the clinical pathway for Plinabulin in the U.S., with a focus on the design of a second Phase 3 study for CIN.

4. Bad News, Challenges, or Points of Concern:

• Regulatory Hurdles: The FDA requires additional data for U.S. approval of Plinabulin for CIN, necessitating a second Phase 3 study.
• Market Concerns: The majority of clinical data for NSCLC is derived from Chinese patients, raising questions about its applicability to the U.S. population.
• Increased G&A Expenses: Full-year G&A expenses rose significantly, indicating higher pre-commercialization costs that may not be sustainable.

5. Notable Q&A Insights:

• Management expressed optimism regarding the ongoing discussions with the NMPA for CIN approval in China, citing positive feedback.
• The FDA's requirement for a second study for CIN in the U.S. is still under discussion, with no definitive timeline provided.
• The company is confident in the quality of its clinical data from China, despite concerns raised about data integrity in previous trials.
• Management indicated a preference to conduct the second study independently, though they remain open to partnerships.

Overall, BeyondSpring is navigating regulatory challenges while maintaining a focus on its strategic initiatives for Plinabulin. The financial metrics show improvement, but the company faces significant hurdles in securing U.S. approvals.